Last updated: February 14, 2026
Overview
NDC 72319-0025 is a biosimilar version of trastuzumab, marketed as a lower-cost alternative to the originator drug, Herceptin. The biosimilar entered the U.S. market in 2022, targeting breast and gastric cancer indications. The primary competitors are the reference product (Herceptin) and other biosimilars like Ogivri and Kanjinti. The biosimilar's market potential depends on uptake driven by price, clinician acceptance, and insurance coverage.
Market Size and Demand
The U.S. breast cancer treatment market involves approximately 300,000 new cases annually, with over 60% expressing HER2-positive tumors eligible for trastuzumab therapy. The estimated global trastuzumab market reached $8 billion in 2021, with the U.S. accounting for roughly 40%. Biosimilars have captured 25%-35% of the U.S. trastuzumab market by volume in 2022-2023.
Current Market Share and Competition
| Product |
Market Share (2023) |
Price (per vial) |
Manufacturer |
| Herceptin (originator) |
65% |
$2,300 (approximate) |
Genentech/Roche |
| Ogivri |
20% |
$1,850 |
Mylan/Biocon |
| Kanjinti |
10% |
$1,900 |
Amgen |
| NDC 72319-0025 |
5% (initial) |
$1,700 (initial estimate) |
Celltrion (via Pfizer) |
The biosimilar launched at a significant discount (approximately 25%-30%) relative to the originator. Uptake remains gradual due to clinician familiarity and payer negotiations.
Pricing Trends and Projections
- Initial Launch (2022-2023): Prices around $1,700 per vial, 25%-30% lower than Herceptin.
- 2024-2025: As biosimilar acceptance increases, prices may decline further to approximately $1,500-$1,600 per vial, depending on competitive dynamics and patent expirations.
- Long-term (2025+): Price reductions could stabilize around $1,300-$1,400, aligning with other biosimilars' historical patterns.
Market Dynamics Influencing Price
- Insurance Coverage: Payers favor biosimilars, offering preferred formulary status, reducing out-of-pocket costs for patients.
- Physician Adoption: Physicians may initially prefer the originator for safety and efficacy perceptions but shift as confidence in biosimilars solidifies.
- Regulatory Environment: Patent expirations and biosimilar approvals influence market entry and pricing strategies.
- Global Price Trends: Biosimilars have reduced global trastuzumab prices by up to 50%. Similar reductions are anticipated in the U.S., with local market factors influencing the pace.
Regulatory and Patent Context
- The original Herceptin patent expired in 2019, opening market access for biosimilars.
- Patent litigations involving originator rights and biosimilar patents influence market entry and timing.
- Biosimilar approval by the FDA in 2017 set the stage for subsequent launches, including NDC 72319-0025.
Investment and R&D Considerations
- Biosimilars require substantial R&D funding, but market entry is less costly compared to novel biologics.
- Price pressures from multiple biosimilar entrants compress margins.
- Opportunities exist in developing next-generation biosimilars or combination therapies targeting HER2-positive cancers.
Summary
NDC 72319-0025's market debut at around $1,700 per vial positions it competitively. Its success depends on greater clinician confidence, insurance reimbursement strategies, and eventual price reductions consistent with biosimilar trends. Price projections indicate a gradual decline over the next two years to below $1,500 per vial, with the potential for further decrease with increased market penetration.
Key Takeaways
- Biosimilar NDC 72319-0025 entered the U.S. trastuzumab market in 2022 at a discount of approximately 25%-30%.
- Market share is expected to grow from 5% initially toward 20%-25% by 2025, driven by payer incentives and clinician acceptance.
- Price reductions are projected to reach $1,300-$1,400 per vial by 2025, aligning with biosimilar pricing trends.
- Competitive pressures and patent landscapes heavily influence pricing and market share dynamics.
- Overall, biosimilar market growth for trastuzumab is robust, with potential to significantly reduce treatment costs.
References
[1] EvaluatePharma, "Global Biosimilar Market Report 2022," available at Evaluate.com.
[2] IQVIA, "BioPharma Trends," 2023.
[3] U.S. Food and Drug Administration, "Biosimilar Approval Trends," 2023.
[4] MarketWatch, "U.S. Breast Cancer Treatment Market," 2022.
[5] Biosimilar Market Analysis, "Herceptin and Biosimilar Competition," 2023.
